Shawn McLane, MD
Pulmonary Disease · Richmond, VANPI 1194741959
Payments from drug & device makers
Across 125 payments — averaging $15.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$371
- Regeneron Healthcare Solutions, Inc.$196
- Mallinckrodt Hospital Products Inc.$159
- Boehringer Ingelheim$147
- Novartis$134
- AstraZeneca$124
- plus $813 from 19 others
What the payments were for
- Food & beverage$1,945100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 32 | $371 |
| Regeneron Healthcare Solutions, Inc. | 10 | $196 |
| Mallinckrodt Hospital Products Inc. | 7 | $159 |
| Boehringer Ingelheim | 9 | $147 |
| Novartis | 9 | $134 |
| AstraZeneca | 9 | $124 |
| Amgen | 5 | $98 |
| Insmed, Inc. | 8 | $98 |
| United Therapeutics Corporation | 6 | $96 |
| Sanofi | 5 | $84 |
| Mylan Specialty L.p. | 4 | $56 |
| Genentech USA, Inc. | 3 | $55 |
| Actelion Pharmaceuticals US, Inc. | 2 | $46 |
| Paratek Pharmaceuticals, Inc. | 3 | $37 |
| Mallinckrodt Enterprises LLC | 2 | $36 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Atricure, Inc. | 1 | $26 |
| Grifols USA, LLC | 1 | $25 |
| Electromed, Inc. | 2 | $23 |
| Baxter Healthcare | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $17 |
| Pharming Healthcare, Inc. | 1 | $15 |
| Sandoz | 1 | $12 |
| Circassia Inc. | 1 | $12 |
How this compares
$1,945 in reported general payments places this provider in the 45th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 628 | $472,744 |
| OfevNintedanib Esylate | 12 | $156,049 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 11 | $136,580 |
| Breo ElliptaFluticasone/Vilanterol | 216 | $95,483 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 115 | $69,380 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 99 | $61,210 |
| Spiriva RespimatTiotropium Bromide | 95 | $55,191 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 68 | $48,523 |
| SymbicortBudesonide/Formoterol Fumarate | 89 | $25,866 |
| Spiriva HandihalerTiotropium Bromide | 42 | $24,264 |
| Incruse ElliptaUmeclidinium Bromide | 47 | $18,018 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 650 | $16,105 |
| Arnuity ElliptaFluticasone Furoate | 40 | $14,500 |
| DuleraMometasone/Formoterol | 39 | $14,438 |
| Qvar RedihalerBeclomethasone Dipropionate | 32 | $10,170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $371 | $670,1241,046 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $147 | $272,451206 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $124 | $74,388157 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Richmond
- Shilpa JohriRichmond$1.7M
- Patricia SimeRichmond$572K
- Apostolos PerelasRichmond$567K
- Ray ShepherdRichmond$303K
- Sujoy GillRichmond$296K
- Glenn GiesselRichmond$267K
- Marjolein DewitRichmond$214K
- Nauman ChaudaryRichmond$77K
- Ritsu KunoRichmond$64K
- Daniel GrinnanRichmond$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.